Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma, Kaposi 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1HIV Infections 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Specimen Handling 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Antiretroviral Therapy, Highly Active × Dermatologic × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡